Fast Skeletal Muscle Troponin and Tropomyosin as a Dietary Source of Antidiabetic and Antihypertensive Bioactive Peptides: An In Silico Study
Open Access
- 3 February 2023
- journal article
- research article
- Published by Universidad de Antioquia in Vitae
- Vol. 30 (1)
Abstract
Background : The nutraceutical properties of food hydrolysates rely on multiple biochemical interactions involving the modulation of enzymes and cellular receptors. Numerous bioactive peptides released from troponin and tropomyosin digestion have been identified. Their characterization has mostly been performed by hydrolysis catalyzed by proteases unrelated to the human digestive system. Objective: This study aimed to determine the bioactive profile of beef, pork, and chicken meat by analyzing the frequency and pharmacokinetics of biopeptides released from troponin and tropomyosin. Methods: In silico digestion and biopeptide release frequency were studied by three parameters; bioactive fragments release frequency (AE), frequency percentage (W), and mean occurrence (AS), all stated on the BIOPEP-UWM platform. Further on, hydrolysis end-products were screened based on gastrointestinal-absorption probability and pharmacokinetic profiling performed on SwissADME, SwissTargetPrediction, and ADME/Tlab bioinformatics web tools. Statistical analyses were performed using a one-way ANOVA test. Results: Dipeptidyl peptidase-IV (DPP-IV) and angiotensin-converting enzyme (ACE) inhibiting biopeptides exhibited the highest release frequency. Moreover, W and AS parameters showed no significant difference (p>0.05) between the myofibrillar isoforms assessed. Seven biopeptides were classified as highly absorbable and reported optimal drug-likeness compliance. Although biopeptides hold good pharmacokinetic properties, the therapeutic potency of biopeptides showed to be lower than those of DPP-IV and ACE-inhibiting drugs. Conclusions: Troponin and tropomyosin are rich dietary sources of bioactive peptides, mainly DPP-IV and ACE inhibitors. Digestion end-products are mainly dipeptides with optimal pharmacokinetic and drug-like properties, suggesting a potential therapeutic application in hypertensive and hyperglycemic disorders.Keywords
This publication has 54 references indexed in Scilit:
- Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cellsMetabolism, 2014
- Time of effect duration and administration interval for sitagliptin in patients with kidney failureEuropean Journal of Drug Metabolism and Pharmacokinetics, 2013
- Inhibition of dipeptidyl peptidase IV and xanthine oxidase by amino acids and dipeptidesFood Chemistry, 2013
- Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injuryKidney International, 2012
- Bioactive Peptides from Muscle Sources: Meat and FishNutrients, 2011
- ADME Evaluation in Drug Discovery. 9. Prediction of Oral Bioavailability in Humans Based on Molecular Properties and Structural FingerprintsMolecular Pharmaceutics, 2011
- Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failureInternational Journal of Molecular Medicine, 2010
- Purification and identification of novel angiotensin-I-converting enzyme inhibitory peptides from shark meat hydrolysateProcess Biochemistry, 2008
- Ca2+-calmodulin-dependent phosphodiesterase (PDE1): Current perspectivesCellular Signalling, 2005
- Current Perspectives on Established and Putative Mammalian Oligopeptide TransportersJournal of Pharmaceutical Sciences, 2003